Medtentia is a cardiovascular device company that is developing new transformative solutions for mitral valve repair based on its proprietary helix annuloplasty ring technology.
The Company’s lead product, CathHELIX® is a transcatheter mitral valve repair system that is designed to overcome the debilitating effects of mitral regurgitation or “leaky valve,” the most common heart valve disorder that affects 2% of the population and 10% of individuals aged over 75. Mitral regurgitation severely limits physical activity and quality of life and, if left untreated, leads to heart failure and death.
CathHELIX® is a catheter-based treatment that has the potential to provide a significantly less invasive treatment option while still retaining the clinical efficacy of surgical mitral valve repair, which is the current gold standard.
CathHELIX® is designed to be routinely used by interventional cardiologists and is intended to provide a new treatment option for patients suffering from mitral valve disease. This includes the vast majority of patients who are in need of treatment but are unable to undergo invasive surgical procedures.
ADVANCED DEVELOPMENT STAGE
Medtentia’s proprietary surgical helix annuloplasty ring has been studied in an 11-patient clinical study. Data from this completed study have validated the helix technology as being safe, effective and easy to use.
CathHELIX® is currently in late pre-clinical development.
STRONG IP PORTFOLIO
40+
FILED PATENT FAMILIES
CathHELIX® and the Company’s helix technology is protected by a growing portfolio of over 40 filed patent families.
INVESTORS
Medtentia is a private company financed by leading Nordic venture capital companies and a group of private investors.
HISTORY
Founded in Sweden in 2002, the company was originally called Medtentia AB.
In 2009 activities and headquarters were transferred to Finland and the company was renamed Medtentia International Ltd Oy.
Medtentia is ISO13485 certified.